Loading...

Orthocell Limited

OCC.AXASX
Healthcare
Biotechnology
A$1.26
A$-0.01(-1.18%)

Orthocell Limited (OCC.AX) Company Profile & Overview

Explore Orthocell Limited’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Orthocell Limited (OCC.AX) Company Profile & Overview

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.

SectorHealthcare
IndustryBiotechnology
CEOPaul Frederick Anderson

Contact Information

61 8 9360 2888
Building 191, Murdoch, WA, 6150

Company Facts

IPO DateAug 12, 2014
CountryAU
Actively Trading

Frequently Asked Questions

;